Dynamic Technology Lab Private Ltd Purchases New Position in Icon Plc $ICLR

Dynamic Technology Lab Private Ltd acquired a new position in shares of Icon Plc (NASDAQ:ICLR) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 4,553 shares of the medical research company’s stock, valued at approximately $797,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Muhlenkamp & Co. Inc. bought a new position in shares of Icon in the 3rd quarter valued at $12,857,000. Mitchell Capital Management Co. bought a new stake in Icon during the 3rd quarter worth $1,627,000. First National Bank of Omaha bought a new stake in Icon during the 3rd quarter worth $6,267,000. Tributary Capital Management LLC increased its holdings in Icon by 84.5% in the 3rd quarter. Tributary Capital Management LLC now owns 11,752 shares of the medical research company’s stock worth $2,057,000 after purchasing an additional 5,381 shares in the last quarter. Finally, Stephens Investment Management Group LLC raised its position in Icon by 15.7% in the third quarter. Stephens Investment Management Group LLC now owns 480,104 shares of the medical research company’s stock valued at $84,018,000 after purchasing an additional 65,264 shares during the last quarter. Institutional investors own 95.61% of the company’s stock.

Analyst Ratings Changes

ICLR has been the topic of a number of recent research reports. BMO Capital Markets reissued a “market perform” rating and set a $100.00 price target on shares of Icon in a research note on Thursday, February 12th. Leerink Partners reaffirmed a “market perform” rating and issued a $105.00 price objective on shares of Icon in a research note on Thursday, February 12th. TD Cowen upgraded shares of Icon from a “hold” rating to a “buy” rating and dropped their price objective for the company from $183.00 to $120.00 in a report on Wednesday, February 18th. Rothschild & Co Redburn set a $100.00 target price on shares of Icon and gave the stock a “neutral” rating in a research report on Tuesday, February 17th. Finally, Mizuho set a $216.00 target price on shares of Icon in a report on Friday, January 9th. Six equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $152.13.

Icon Trading Up 2.6%

NASDAQ ICLR opened at $110.03 on Tuesday. The firm has a market capitalization of $8.89 billion, a PE ratio of 14.89, a price-to-earnings-growth ratio of 2.75 and a beta of 1.36. The business’s 50-day moving average price is $150.65 and its two-hundred day moving average price is $167.41. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.31. Icon Plc has a 12 month low of $66.57 and a 12 month high of $211.00.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.